This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tormo, D. Articles by Tüting, T. Search for Related Content PubMed PubMed Citation Articles by Tormo, D. Articles by Tüting, T.

Therapeutic Efficacy of Antigen-Specific Vaccination and Toll-Like Receptor Stimulation against Established Transplanted and Autochthonous Melanoma in Mice

Laboratory of Experimental Dermatology, Department of Dermatology, University of Bonn, Bonn, Germany

Requests for reprints: Thomas Tüting, Laboratory of Experimental Dermatology, Department of Dermatology, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany. Phone: 49-228-287-9257; Fax: 49-228-287-9393; E-mail: thomas.tueting{at}ukb.uni-bonn.de.

Malignant melanoma is an attractive model disease for the development of antigen-specific immunotherapy because many antigens recognized by tumor-specific T cells have been identified. In C57BL/6 mice, genetic immunization with recombinant adenovirus encoding xenogeneic human tyrosinase-related protein 2 (Ad-hTRP2) induces protective but not therapeutic cellular immunity against growth of transplanted B16 melanoma cells. Here, we additionally applied CpG DNA and synthetic double-stranded RNA, which activate the innate immune system via Toll-like receptors (TLR). Both adenoviral vaccination and peritumoral injections of TLR ligands were required for rejection of established B16 melanoma in the skin. To more closely mimic the clinical situation in patients with melanoma, we evaluated this combined immunotherapeutic strategy in genetically modified mice, which overexpress hepatocyte growth factor (HGF) and carry an oncogenic mutation in the cyclin-dependent kinase 4 (CDK4)^R24C. HGF x CDK4^R24C mice rapidly develop multiple invasive melanomas in the skin following neonatal carcinogen treatment, which spontaneously metastasize to lymph nodes and lungs. Vaccination with Ad-hTRP2 followed by injections of TLR ligands resulted in delayed growth of autochthonous primary melanomas in the skin and reduction in the number of spontaneous lung metastases but did not induce tumor regression. Carcinogen-treated HGF x CDK4^R24C mice bearing multiple autochthonous melanomas did not reject transplanted B16 melanoma despite treatment with Ad-hTRP2 and TLR ligands, suggesting the development of tumor immunotolerance. Further investigations in our novel genetic melanoma model may help to better understand the role of the immune system in the pathogenesis and treatment of this life-threatening disease. (Cancer Res 2006; 66(10): 5427-35)

This article has been cited by other articles:

				H. Qin, S.-c. Cha, S. S. Neelapu, Y. Lou, J. Wei, Y.-J. Liu, and L. W. Kwak Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity Blood, November 5, 2009; 114(19): 4142 - 4149. [Abstract] [Full Text] [PDF]

				J. Kohlmeyer, M. Cron, J. Landsberg, T. Bald, M. Renn, S. Mikus, S. Bondong, D. Wikasari, E. Gaffal, G. Hartmann, et al. Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy Cancer Res., August 1, 2009; 69(15): 6265 - 6274. [Abstract] [Full Text] [PDF]

				D. Anz, R. Thaler, N. Stephan, Z. Waibler, M. J. Trauscheid, C. Scholz, U. Kalinke, W. Barchet, S. Endres, and C. Bourquin Activation of Melanoma Differentiation-Associated Gene 5 Causes Rapid Involution of the Thymus J. Immunol., May 15, 2009; 182(10): 6044 - 6050. [Abstract] [Full Text] [PDF]

				O. M. Grauer, J. W. Molling, E. Bennink, L. W. J. Toonen, R. P. M. Sutmuller, S. Nierkens, and G. J. Adema TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas J. Immunol., November 15, 2008; 181(10): 6720 - 6729. [Abstract] [Full Text] [PDF]

				A. J. Currie, R. G. van der Most, S. A. Broomfield, A. C. Prosser, M. G. Tovey, and B. W. S. Robinson Targeting the Effector Site with IFN-{alpha}{beta}-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors J. Immunol., February 1, 2008; 180(3): 1535 - 1544. [Abstract] [Full Text] [PDF]